{"id":744973,"date":"2014-06-02T06:30:00","date_gmt":"2014-06-02T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/"},"modified":"2023-03-22T00:04:54","modified_gmt":"2023-03-22T04:04:54","slug":"first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/","title":{"rendered":"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014"},"content":{"rendered":"<p class=\"bwalignc\">       Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor        Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive,        Advanced NSCLC Patients     <\/p>\n<p class=\"bwalignc\">       Merck Initiating Phase 3 Study with Pembrolizumab Versus        Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1        Positive, Advanced NSCLC (KEYNOTE-024)     <\/p>\n<p class=\"bwalignc\">       Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned        Using Merck\u2019s Proprietary PD-L1 Assay at One Percent and 50 Percent Cut        Points     <\/p>\n<p>CHICAGO&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of data evaluating pembrolizumab<br \/>\n      (MK-3475), Merck\u2019s investigational anti-PD-1 antibody, as initial<br \/>\n      therapy in patients with PD-L1 positive, advanced non-small cell lung<br \/>\n      cancer (NSCLC). In previously-untreated patients, the objective response<br \/>\n      rate (ORR) (confirmed and unconfirmed) with pembrolizumab as a<br \/>\n      single-agent (monotherapy) was 47 percent by investigator-assessed,<br \/>\n      immune-related response criteria (irRC) (n=21\/45: 95% CI, 32-62) and 26<br \/>\n      percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria<br \/>\n      in Solid Tumors) (n=11\/42: 95% CI, 14-42). In evaluable patients who had<br \/>\n      measurable disease with one post baseline scan, 80 percent demonstrated<br \/>\n      tumor shrinkage as measured by centrally evaluated RECIST criteria<br \/>\n      (n=28\/35). The median duration of response has not been reached, with<br \/>\n      some patients continuing on treatment with pembrolizumab as monotherapy<br \/>\n      for at least one year.\n    <\/p>\n<p>\n      These new data, from the company\u2019s large ongoing Phase 1b study<br \/>\n      (KEYNOTE-001), will be presented today in an oral session by Dr. Naiyer<br \/>\n      Rizvi, medical oncologist, Thoracic Oncology Service, Memorial Sloan<br \/>\n      Kettering Cancer Center, at the 50<sup>th<\/sup> Annual Meeting of the<br \/>\n      American Society of Clinical Oncology (ASCO 2014) in Chicago (Abstract<br \/>\n      #8007; 3:00 PM CDT; Location \u2013 E Hall D2).\n    <\/p>\n<p>\n      \u201cThese initial data show that early use of pembrolizumab as monotherapy<br \/>\n      provides robust anti-tumor activity in patients with<br \/>\n      previously-untreated, advanced non-small cell lung cancer,\u201d said Dr.<br \/>\n      Rizvi. \u201cToday, there are few options for people with advanced lung<br \/>\n      cancer and early data suggests that pembrolizumab, which activates the<br \/>\n      body\u2019s immune system to target cancer cells, may be a promising new<br \/>\n      approach.\u201d\n    <\/p>\n<p>\n      <b>First Data for Pembrolizumab as Initial Therapy in Advanced Lung<br \/>\n      Cancer<\/b>\n    <\/p>\n<p>\n      Data to be presented from a cohort of KEYNOTE-001, the largest Phase 1b<br \/>\n      study to date of an anti-PD-1 antibody, evaluated pembrolizumab<br \/>\n      monotherapy as initial therapy in patients with stage IV NSCLC who had<br \/>\n      no prior systemic therapy and whose tumors were assessed as positive for<br \/>\n      PD-L1 expression. As measured by Merck\u2019s proprietary,<br \/>\n      immunohistochemistry (IHC) trial assay, tumors were classified as PD-L1<br \/>\n      positive based on greater than or equal to one percent of tumor cells<br \/>\n      demonstrating expression of the PD-L1 marker, or any positive staining<br \/>\n      with the same reagent in tumor stroma. In the study cohort, 78 percent<br \/>\n      of evaluable advanced NSCLC patients were determined to be PD-L1<br \/>\n      positive (n=57\/73).\n    <\/p>\n<p>\n      <b>Objective Response Rates (ORR) and Disease Control Rates (DCR) in<br \/>\n      Advanced NSCLC, as Assessed by irRC and RECIST Criteria<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<p class=\"bwcellpmargin\">\n            <b>Dose<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"5\">\n          <b>irRC, <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>Investigator Review<\/b>\u2020\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"5\">\n          <b>RECIST v1.1, <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>Central Review<\/b><sup>1<\/sup>\u2020\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          n\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          ORR<\/p>\n<p class=\"bwcellpmargin\">\n            n (%)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            [95% CI]\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          DCR<\/p>\n<p class=\"bwcellpmargin\">\n            n (%)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            [95% CI]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          n\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          ORR<\/p>\n<p class=\"bwcellpmargin\">\n            n (%)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            [95% CI]\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          DCR<\/p>\n<p class=\"bwcellpmargin\">\n            n (%)\n          <\/p>\n<p class=\"bwcellpmargin\">\n            [95% CI]\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          2 mg\/kg Q3W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          4 (67%)<\/p>\n<p class=\"bwcellpmargin\">\n            [22%-96%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          5 (83%)<\/p>\n<p class=\"bwcellpmargin\">\n            [36%-100%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          2 (33%)<\/p>\n<p class=\"bwcellpmargin\">\n            [4%-78%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          3 (50%)<\/p>\n<p class=\"bwcellpmargin\">\n            [12%-88%]\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          10 mg\/kg Q3W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          22\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          10 (46%)<\/p>\n<p class=\"bwcellpmargin\">\n            [24%-68%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          18 (82%)<\/p>\n<p class=\"bwcellpmargin\">\n            [60%-95%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          20\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          4 (20%)<\/p>\n<p class=\"bwcellpmargin\">\n            [6%-44%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          14 (70%)<\/p>\n<p class=\"bwcellpmargin\">\n            [46%-88%]\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          10 mg\/kg Q2W\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          17\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          7 (41%)<\/p>\n<p class=\"bwcellpmargin\">\n            [18%-67%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          12 (71%)<\/p>\n<p class=\"bwcellpmargin\">\n            [44%-90%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          16\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          5 (31%)<\/p>\n<p class=\"bwcellpmargin\">\n            [11%-59%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          10 (63)<\/p>\n<p class=\"bwcellpmargin\">\n            [35%-85%]\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          TOTAL\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          45\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          21 (47%)<\/p>\n<p class=\"bwcellpmargin\">\n            [32%-62%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          35 (78%)<\/p>\n<p class=\"bwcellpmargin\">\n            [63%-89%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          42\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          11 (26%)<\/p>\n<p class=\"bwcellpmargin\">\n            [14%-42%]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          27 (64%)<\/p>\n<p class=\"bwcellpmargin\">\n            [48%-78%]\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      Analysis cut-off date: 03 March 2014<br \/>Objective response rate =<br \/>\n      confirmed complete response and partial response<br \/>Disease control<br \/>\n      rate = complete response, partial response, and stable disease<br \/><sup>1<\/sup>3<br \/>\n      patients did not have measurable disease by RECIST v1.1 per independent<br \/>\n      central review at baseline and were not evaluated for response using<br \/>\n      this criteria<br \/>\u2020Includes confirmed and unconfirmed responses\n    <\/p>\n<p>\n      At the time of analysis, 90 percent (n=19\/21) and 100 percent (n=11\/11)<br \/>\n      of overall responses (confirmed and unconfirmed) in evaluable patients<br \/>\n      were ongoing by irRC and RECIST criteria, respectively. None of the<br \/>\n      responders discontinued treatment due to progression of disease. The<br \/>\n      interim, median progression-free survival (PFS) was 37 weeks by irRC<br \/>\n      (95% CI, 27.0-NR) and 27 weeks by RECIST (95% CI, 13.6-45.0). The<br \/>\n      interim, median duration of treatment among evaluable patients with<br \/>\n      ongoing responses was 27.1 weeks based on both measurement criteria<br \/>\n      (irRC range, 6.1 \u2013 57.1+) (RECIST range, 15.0+ &#8211; 48.3+).\n    <\/p>\n<p>\n      Adverse events were consistent with previously reported data for<br \/>\n      pembrolizumab. The most common investigator-assessed, treatment-related,<br \/>\n      adverse events (greater than 5 percent) included fatigue (22%), pruritus<br \/>\n      (13%), hypothyroidism (9%), dermatitis acneiform (7%), diarrhea (7%),<br \/>\n      dyspnea (7%), and rash (7%). Investigator-designated, treatment-related,<br \/>\n      adverse events resulting in discontinuation were pneumonitis (one grade<br \/>\n      3) and acute kidney injury (one grade 2). Other investigator-designated,<br \/>\n      treatment-related, adverse events included pericardial effusion (one<br \/>\n      grade 3) and elevated blood creatine phosphokinase levels (one grade 4).\n    <\/p>\n<p>\n      <b>New Studies in PD-L1 Positive, Advanced Lung Cancer<\/b>\n    <\/p>\n<p>\n      Based on these data, Merck has enrolled 50 additional patients in the<br \/>\n      KEYNOTE-001 study with previously-untreated, advanced NSCLC with PD-L1<br \/>\n      positive-staining tumors. For this cohort, cut points of greater than or<br \/>\n      equal to one percent and 50 percent tumor cells stained will be<br \/>\n      evaluated as part of the efficacy analysis. Additionally, Merck plans to<br \/>\n      initiate a Phase 3 study (KEYNOTE-024) evaluating pembrolizumab<br \/>\n      monotherapy versus platinum-based doublet chemotherapy (cisplatin,<br \/>\n      carboplatin combined with either: docetaxel, paclitaxel, vinorelbine,<br \/>\n      gemcitabine or irinotecan) in previously-untreated patients with PD-L1<br \/>\n      positive, advanced NSCLC in September 2014.\n    <\/p>\n<p>\n      \u201cAs clinical experience with pembrolizumab grows in advanced non-small<br \/>\n      cell lung cancer we are seeing durable responses across multiple lines<br \/>\n      of therapy, including in the first-line treatment setting,\u201d said, Dr.<br \/>\n      Roy Baynes, senior vice president, Global Clinical Development, Merck<br \/>\n      Research Laboratories. \u201cExploring the clinical utility of tumor<br \/>\n      characteristics, such as expression of PD-L1 as a potential marker for<br \/>\n      patient selection or study enrichment, is an important part of our<br \/>\n      research program in this disease.\u201d\n    <\/p>\n<p>\n      <b>Additional Advanced Lung Cancer Data at ASCO 2014<\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmercks-investigational-anti-pd1-antibody-mk-3475-active-three-differe&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=New+data+evaluating+pembrolizumab+in+previously-treated+NSCLC&amp;index=1&amp;md5=a4bfaade08900b5129202c43106328bc\" rel=\"nofollow\">New<br \/>\n      data evaluating pembrolizumab in previously-treated NSCLC<\/a> including<br \/>\n      findings from an additional study cohort will be presented in a poster<br \/>\n      discussion on Tuesday, June 3 (Abstract #8020; 8:00 AM CDT; Location \u2013<br \/>\n      E354b). For more information about data in advanced NSCLC, see the ASCO<br \/>\n      iPlanner: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fiplanner.asco.org%2Fam2014&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=https%3A%2F%2Fiplanner.asco.org%2Fam2014&amp;index=2&amp;md5=cade2bb0657c4a964bc505c6a3be0a32\" rel=\"nofollow\">https:\/\/iplanner.asco.org\/am2014<\/a><span class=\"bwuline\">.<\/span>\n    <\/p>\n<p>\n      <b>Merck Oncology Briefing Webcast<\/b>\n    <\/p>\n<p>\n      Merck will hold a webcast in conjunction with ASCO 2014 on June 2 at<br \/>\n      6:15 p.m. CDT. Investors and journalists may access a live audio webcast<br \/>\n      of the event on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=869c12675d20fe715840b3358e641249\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>.&nbsp;Software<br \/>\n      needed to listen to the webcast is available on the corporate website<br \/>\n      and should be downloaded prior to the beginning of the<br \/>\n      webcast.&nbsp;Institutional investors, analysts and members of the media also<br \/>\n      can also listen to the event by dialing (866) 486-2604 or (706) 902-0743<br \/>\n      and using ID code number 53194490.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-001 Study<\/b>\n    <\/p>\n<p>\n      The Phase 1b trial (KEYNOTE-001) is an ongoing multi-center, single-arm,<br \/>\n      open-label study evaluating pembrolizumb monotherapy in more than 1,000<br \/>\n      patients with diverse late-stage cancers (metastatic carcinoma) \u2013<br \/>\n      predominantly lung and melanoma. Three dosing regimens of pembrolizumab<br \/>\n      were evaluated, including 10mg\/kg every two weeks, 10mg\/kg every three<br \/>\n      weeks or 2mg\/kg every three weeks. The primary endpoint of the study<br \/>\n      includes overall response rate (ORR) and safety; the secondary endpoints<br \/>\n      include progression-free survival (PFS), overall survival (OS) and<br \/>\n      duration of response. Tumor response in advanced NSCLC was evaluated<br \/>\n      every 9 weeks by investigator-assessed, immune-related response criteria<br \/>\n      (irRC), and by independent, central, blinded radiographic review per<br \/>\n      RECIST 1.1 (Response Evaluation Criteria in Solid Tumors).\n    <\/p>\n<p>\n      <b>About Pembrolizumab in Advanced Lung Cancer<\/b>\n    <\/p>\n<p>\n      Pembrolizumab (MK-3475) is an investigational, selective, humanized,<br \/>\n      monoclonal anti-PD-1 antibody designed to block the interaction of PD-1<br \/>\n      on T-cells with its ligands, PD-L1 and PD-L2, to reactivate anti-tumor<br \/>\n      immunity. Pembrolizumab exerts dual ligand blockade of the PD-1 pathway.\n    <\/p>\n<p>\n      Pembrolizumab is being evaluated across more than 30 types of cancers,<br \/>\n      as monotherapy and in combination. Merck is advancing a clinical program<br \/>\n      in advanced NSCLC evaluating pembrolizumab as monotherapy and in<br \/>\n      combination across lines of therapy, and is exploring different tumor<br \/>\n      characteristics such as PD-L1 expression as predictors of<br \/>\n      responsiveness. For information about Merck\u2019s oncology clinical studies,<br \/>\n      please click <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=ec0013cd7421254b9dbbb5c2fe13f205\" rel=\"nofollow\">here<\/a>.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer has been the most common cancer in the world, other than<br \/>\n      skin cancer. In the U.S. there will be an estimated 159,260 deaths from<br \/>\n      lung cancer in 2014. Lung cancer is divided into two major types:<br \/>\n      non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).<br \/>\n      NSCLC is the most common type of lung cancer \u2013 accounting for &gt; 85<br \/>\n      percent of all lung cancers.\n    <\/p>\n<p>\n      <b>About Merck Oncology: A Focus on Immuno-Oncology<\/b>\n    <\/p>\n<p>\n      At Merck Oncology, our goal is to translate breakthrough science into<br \/>\n      biomedical innovations to help people with cancer worldwide. Harnessing<br \/>\n      immune mechanisms to fight cancer is the priority focus of our oncology<br \/>\n      research and development program. The Company is advancing an early and<br \/>\n      late-stage pipeline of immunotherapy candidates and combination<br \/>\n      regimens. Cancer is one of the world&#8217;s most urgent unmet medical needs.<br \/>\n      Helping to empower people to fight cancer is our passion. For<br \/>\n      information about Merck\u2019s commitment to Oncology visit the Oncology<br \/>\n      Information Center at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Foncology-infocenter&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.mercknewsroom.com%2Foncology-infocenter&amp;index=5&amp;md5=9108bff1f6505c43df51faa8cbecce92\" rel=\"nofollow\">http:\/\/www.mercknewsroom.com\/oncology-infocenter<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=558ffe1047bc247fb80542a69f310a5e\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=1333b7bcbb95c693385ac2f04a7f17a2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=90771cbbad9534a382c0feaac18349be\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=964ef70c44b42ff1a54e0b85264e6d8f\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50877308&amp;newsitemid=20140602005552&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=d3dae982cfacc58a059c4f7ffa81af2b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140602005552r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Ian McConnell, (973) 901-5722<br \/>or<br \/>Claire        Mulhearn, (908) 423-7425<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, (908) 423-4465<br \/>or<br \/>Justin Holko, (908) 423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck\u2019s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). In previously-untreated patients, the objective response rate (ORR) (confirmed and unconfirmed) with pembrolizumab as a single-agent (monotherapy) was 47 percent by investigator-assessed, immune-related response criteria (irRC) (n=21\/45: 95% CI, 32-62) and 26 percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (n=11\/42: 95% CI, 14-42). In evaluable patients who had measurable disease with one post baseline scan, 80 percent demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria (n=28\/35). The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[137,138,289,56],"class_list":["post-744973","news_item","type-news_item","status-publish","hentry","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck\u2019s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). In previously-untreated patients, the objective response rate (ORR) (confirmed and unconfirmed) with pembrolizumab as a single-agent (monotherapy) was 47 percent by investigator-assessed, immune-related response criteria (irRC) (n=21\/45: 95% CI, 32-62) and 26 percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (n=11\/42: 95% CI, 14-42). In evaluable patients who had measurable disease with one post baseline scan, 80 percent demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria (n=28\/35). The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\\\/\",\"name\":\"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-06-02T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/","og_locale":"en_US","og_type":"article","og_title":"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck\u2019s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). In previously-untreated patients, the objective response rate (ORR) (confirmed and unconfirmed) with pembrolizumab as a single-agent (monotherapy) was 47 percent by investigator-assessed, immune-related response criteria (irRC) (n=21\/45: 95% CI, 32-62) and 26 percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (n=11\/42: 95% CI, 14-42). In evaluable patients who had measurable disease with one post baseline scan, 80 percent demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria (n=28\/35). The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/","name":"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-06-02T06:30:00+00:00","dateModified":"2023-03-22T04:04:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-presentation-of-data-for-pembrolizumab-mercks-investigational-anti-pd-1-antibody-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer-nsclc-at-asco-2014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"First Presentation of Data for Pembrolizumab, Merck\u2019s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"006219b7-ee94-4196-adba-f1ce5c847758","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/First-Presentation-of-Data-for-Pembrolizumab-Mercks-Investigational-Anti-PD-1-Antibody-in-Patients-with-Previously-Untreated-Advanced-TLWUW.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744973\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744973"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}